Evidence map›Paper›PMID 34814861›Full record

ArticleBMC cancer2021

Survival-associated N

Jialin Qu, Li Wang, Man Jiang, Zhimin Wei, Guangming Fu, Xiaochun Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Development and validation of a mFrontiers in oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jialin Qu *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, 250117, China.
Li Wang *Department of Oncology, Jiujiang University Affiliated Hospital, Jiujiang, 332000, China.
Man JiangCancer Precision Medicine Center, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China.
Zhimin WeiPathology Department, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China.
Guangming FuPathology Department, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China.
Xiaochun ZhangCancer Precision Medicine Center, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China. zxc9670@qdu.edu.cn.
Affiliated Hospital of Qingdao University · CNQingdao University · CNJiujiang University · CNShandong Tumor Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundN

methodsWe integrated three m

resultsThe results of the study showed that the expression of the three m

conclusionsOur study showed that the molecular phenotype based on the expression of METTL3 may be an independent risk factor affecting the prognosis of lung squamous cell carcinoma. These findings not only prove the important role of m

Indexed as

AdenineAdenosineAgedCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDatabases, GeneticFemaleGene ExpressionHumansImmunohistochemistryLung NeoplasmsMaleMethylationMethyltransferasesMiddle AgedPrincipal Component AnalysisAdenineAdenosineMethyltransferasesMETTL3 protein, humanN(6)-methoxyadenineN(6)-ribosyladenineRNA, MessengerBioinformatic analysisEpigeneticsLung squamous cell carcinomaN6-methyladeninePrognostic model

Identifiers

PMID34814861
PMCPMC8611943
OpenAlexW3216053169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.